What is the progress related to roselixizumab?

Rozanolixizumab (Rozanolixizumab), as a new FcRn inhibitor, has attracted widespread attention around the world in recent years. Led by the Belgian company UCB, the drug has been highly praised for its ability to target pathogenic IgG antibodies since early clinical trials. Its main treatment targets are patients with generalized myasthenia gravis (gMG; a rare disease), and it has important therapeutic significance especially for individuals who have insufficient response to traditional immunosuppressive treatment.

At present, roselixizumab has been approved for marketing in the United States, Europe, Japan and other regions for the treatment of AChR antibody-positive gMG patients. It is the first FcRn-targeting antibody to show efficacy in MuSK antibody-positive people. This breakthrough result also means that its clinical applicable population has been significantly expanded, filling the gap in the treatment of some refractory myasthenia. Its injection form is subcutaneous administration, which reduces the patient's medication burden and effectively avoids systemic side effects caused by large-dose intravenous injection.

In a series of global research updates announced at the end of 2024, roselixizumab has also been explored for the treatment of multiple autoimmune diseases, such as chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenia (ITP). Preliminary data have shown good IgG-lowering effects and clinical improvement trends, which indicates that its potential indication pipeline may be further expanded.

In China, it was officially approved for marketing in May 2025, becoming the first biologically targeted drug in China that can be applied to both AChR and MuSK antibody-positive patients. This node marks a major leap forward in the field of neuroimmunotherapy in China. Currently, UCB is cooperating with hospitals in many places to conduct post-marketing real-world research in order to provide data support for medical insurance negotiations and large-scale promotion.

Reference materials:https://www.drugs.com/rystiggo.html